RNA Cash-Secured Put Strategy

RNA (Atrium Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

RNA (Atrium Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $208.2M, a beta of 0.37 versus the broader market, a 52-week range of 11.13-16.77, average daily share volume of 202K, a public-listing history dating back to 2026, approximately 511 full-time employees. These structural characteristics shape how RNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.37 indicates RNA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a cash-secured put on RNA?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

RNA snapshot

As of August 14, 2026, spot at $13.14, ATM IV 18.60%, IV rank 10.50%, expected move 5.33%. The cash-secured put on RNA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 154-day expiry.

Why this cash-secured put structure on RNA specifically: RNA IV at 18.60% is on the cheap side of its 1-year range, which means a premium-selling RNA cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 5.33% (roughly $0.70 on the underlying). The 154-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on RNA should anchor to the underlying notional of $13.14 per share and to the trader's directional view on RNA stock.

RNA cash-secured put setup

The RNA cash-secured put below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RNA at $13.14 on that close, the first option leg uses a $12.48 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RNA chain at a 154-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RNA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Sell 1	Put	$12.48	N/A

RNA cash-secured put risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

RNA cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on RNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on RNA

Cash-secured puts on RNA earn premium while a trader waits to acquire RNA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RNA.

RNA thesis for this cash-secured put

The market-implied 1-standard-deviation range for RNA extends from approximately $12.44 on the downside to $13.84 on the upside. A RNA cash-secured put lets a trader earn premium while waiting to acquire RNA at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current RNA IV rank near 10.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RNA at 18.60%. As a Healthcare name, RNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RNA-specific events.

RNA cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RNA alongside the broader basket even when RNA-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on RNA carry tail risk when realized volatility exceeds the implied move; review historical RNA earnings reactions and macro stress periods before sizing. Always rebuild the position from current RNA chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on RNA?: A cash-secured put on RNA is the cash-secured put strategy applied to RNA (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With RNA stock at $13.14 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed RNA chain strike and the premiums come straight from that session's bid/ask midpoint.
How are RNA cash-secured put max profit and max loss calculated?: Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the RNA cash-secured put priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 18.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RNA cash-secured put?: The breakeven for the RNA cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 5.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on RNA?: Cash-secured puts on RNA earn premium while a trader waits to acquire RNA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RNA.
How does current RNA implied volatility affect this cash-secured put?: RNA ATM IV is at 18.60% with IV rank near 10.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.